Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

[Annual advances in clinical research on mechanical ventilation in management of respiratory failure 2025].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2026
Same author

[Annual progress in chronic obstructive pulmonary disease 2025].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2026
Same author

[A multicenter, prospective, observational study of cough variant asthma in China: clinical features, airway inflammation, and prognosis].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2025
Same author

[Application of digital health technology in remote rehabilitation and long-term management of chronic obstructive pulmonary disease patients].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2025
Same author

A Comparative Study of the Clinical Efficacy of Superselective Adrenal Artery Embolization for Patients with Primary Aldosteronism.

American journal of hypertension·2025
Same author

[Clinical research progress in non-invasive positive pressure ventilation from 2023 to 2024].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2025

相关实验视频

Updated: Jan 18, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K

[严重喘的生物疗法进展]

Z C Zhou1, H T Luo1, X Y Chen1

  • 1Department of Allergy and Clinical Immunology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, Guangzhou 510120, China.

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
|September 9, 2025
PubMed
概括

生物药物是严重喘的关键,这种喘对标准治疗没有反应. 本综述涵盖了针对IgE,IL-5和TSLP等关键炎症途径的已批准和正在研究的生物疗法,以更好地治疗喘.

更多相关视频

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

5.1K

相关实验视频

Last Updated: Jan 18, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

5.1K

科学领域:

  • 肺部病理学 肺部病理学
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 严重的支气管喘管理仍然具有挑战性,通常需要额外的治疗方法.
  • 目前的指导方针建议在高剂量吸入性皮质类固醇长效β-激动剂 (ICS-LABA) 治疗中不受控制的患者使用生物药物.
  • 已批准的生物药物针对严重喘相关的特定炎症途径.

研究的目的:

  • 根据其治疗目标,审查和分类目前批准的用于严重喘的生物药物.
  • 总结针对IgE,IL-5/IL-5R,IL-4Rα和TSLP的生物药物的作用机制.
  • 讨论严重喘生物治疗的挑战和未来方向.

主要方法:

  • 对治疗严重喘的已批准和正在研究的生物药物的文献综述.
  • 生物制剂根据其分子标 (例如IgE,IL-5,TSLP) 的分类.
  • 临床应用,挑战和未来趋势的总结.

主要成果:

  • 六种生物药物 (Omalizumab,Mepolizumab,Benralizumab,Reslizumab,Dupilumab,Tezepelumab) 已获得批准,这些药物针对不同的炎症媒介.
  • 这些生物制剂通过抑制关键细胞因子和受体提供有针对性的抗炎作用.
  • 几种新生物药物正在为严重喘进行临床研究.

结论:

  • 生物药物在治疗严重喘方面取得了重大进展.
  • 了解向途径对于优化生物选择和应用至关重要.
  • 持续的研究和开发对于改善严重喘管理的结果至关重要.